Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo

Overview

This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 30, 2019

Detailed Description

This study aims at detection of incidence of metabolic syndrome in vitiligo patients and possible contribution of the age of onset of the disease. This involves detection of waist circumference, body mass index, index of central obesity, systolic and diastolic arterial blood pressure, fasting blood sugar, high density lipoproteins and triglycerides, in addition to insulin resistance as Homeostatic Model Assessment- insulin resisitance (HOMA-IR) and serum leptin in vitiligo patients. The outcomes will be correlated to extent/ severity/duration/ activity of vitiligo as well as to the age of onset. This is assumed to be of profound impact on vitiligo patients by properly assessing these patients for associated metabolic risk factors and helping prevent such metabolic derangements by detection of possible contributing factors such as insulin resistance and high serum adipokines as leptin. Since there is temporal relation between nutrition, metabolic derangements and skin diseases where nutritional deficiencies as minerals, vitamins and fatty acids can lead to cutaneous manifestations and , on the other hand; skin diseases could contribute to metabolic derangements and nutritional deficiencies, the investigator's study will focus on nutrition and dietary habits and there possible contribution to any associated metabolic risk in vitiligo patients. This is likely to open new horizons in the management of vitiligo, possibly through control of metabolic syndrome risk factors and insulin resistance as well as revealing possible temporal relation to dietary habits that are overlooked in vitiligo patients.

Interventions

  • Other: Blood sample
    • Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin

Arms, Groups and Cohorts

  • Vitiligo patients
    • Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
  • controls
    • Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken

Clinical Trial Outcome Measures

Primary Measures

  • Central obesity as a Metabolic risk in vitiligo patients
    • Time Frame: one year
    • Central obesity will be assessed using waist circumference in cm in vitiligo patients and control group as a risk factor for metabolic syndrome

Secondary Measures

  • Arterial Blood Pressure as a Metabolic risk in vitiligo patients
    • Time Frame: one year
    • Arterial Blood Pressure will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
  • Fasting Blood pressure as a Metabolic risk in vitiligo patients
    • Time Frame: one year
    • Fasting Blood pressure will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
  • Serum Triglycerides and HDL
    • Time Frame: one year
    • Serum Triglycerides and HDL will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
  • Body mass index as a Metabolic risk in vitiligo patients
    • Time Frame: one year
    • Body Mass index in kg/m2 will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
  • Detection of insulin resistance in patients with vitiligo
    • Time Frame: one year
    • This is via measuring HOMA-IR
  • Correlation between extent/ severity/duration/ activity of vitiligo and possible associated metabolic derangements.
    • Time Frame: one year
    • This via detecting VASI, VES and VIDA scores for vitiligo patients
  • Correlation between extent/ severity/duration/ activity of vitiligo and the age of onset.
    • Time Frame: one year
    • This via detecting VASI, VES and VIDA scores for vitiligo patients and relating to the age of onset
  • Detection of possible influence of dietary habits and its relation to metabolic derangements and disease progression
    • Time Frame: one year
    • This via directly addressing dietary habits

Participating in This Clinical Trial

Inclusion Criteria

  • Both genders – Patients with non-segmental vitiligo (NSV) and segmental vitiligo Exclusion Criteria:

  • Smoking – Pregnancy – Systemic steroid intake in the last 6 months

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Rania Mogawer, Principal investigator – Cairo University
  • Overall Official(s)
    • Samar El-Tahlawi, MD, Principal Investigator, Cairo university, dermatology department

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.